Company Profile

Spectrasilk Inc
Profile last edited on: 7/14/2014      CAGE: 5CPY7      UEI: SHKPU46NBAJ3

Business Identifier: Silk matrices & tissue regeneration using a silk fibroin possesses for vascular graft engineering
Year Founded
2008
First Award
2010
Latest Award
2012
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

196 Boston Avenue #1700
Medford, MA 02155
   (339) 221-3038
   info@spectrasilk.com
   www.spectrasilk.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Spectrasilk Inc develops products using silk as a material platform across multiple micro-scale and nano-scale technologies by combining the unique features of the silk protein family with technological interfaces like optics and electronics in a single material. The merging of biology and optical physics creates sophisticated, multi-functional, silk-based optical sensing systems with target focus areas in environmental detection, renewable energy, and the life sciences. The silk sensor technology platform enables the detection and monitoring of a variety of contaminants through its versatile chemistry and processing and will directly embed an advanced optical interface offering immediate and easy read out. These systems are biocompatible, disposable, degradable, consumable, and distributable. The distinctive properties offered by silk materials will be at the core of the development of innovative products that address unmet needs across several market areas. Silk fibroin possesses exciting potential for vascular graft engineering with regard to structural tailorability, chemical modification, and drug-loading potential, distinguishing silk from other synthetic and natural materials currently being studied as graft candidates. We will take advantage of the ability to control silk structure and the inherent effects on biodegradation, mechanics, drug loading and release; a graft may be produced with an unprecedented level of control over cell response.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 DARPA $99,962
Project Title: Multifunctional Stabilization Matrix for Biological Samples
2012 1 NIH $150,000
Project Title: Sustained Regeneration Of Soft Tissue Defects
2010 1 NIH $200,000
Project Title: Resorbable Small Diameter Vascular Grafts

Key People / Management

  Eun Seok Gil

  Jonathan Kluge

  Keleigh Sanford

Company News

There are no news available.